Anti-threonyl-tRNA synthetase, a second myositis-related autoantibody by unknown
ANTI-THREONYL-tRNA  SYNTHETASE, 
A  SECOND  MYOSITIS-RELATED  AUTOANTIBODY 
BY  MICHAEL B.  MATHEWS,*  MORRIS REICHLIN,* 
GRAHAM  R.  V.  HUGHES,  § ANt) ROBERT M.  BERNSTEIN *~ 
From the *Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724; the 
*Oklahoma Medical Research Foundation,  Oklahoma City, Oklahoma 73104; and the gRoyal 
Postgraduate Medical School, Hammersmith Hospital, London,  W12 OHS, United Kingdom 
In  the  autoimmune  disease  systemic  lupus  erythematosus  (SLE), 1 antibodies 
reactive with  nuclear  and  cell surface components are a  general  finding  (I,  2). 
By contrast,  in  myositis, an  inflammatory disease of muscle, autoantibodies  are 
often  directed  at  cytoplasmic components  (3).  The  most common target, Jo-1, 
was recently identified  as the  enzyme, histidyl-tRNA  synthetase (4).  Antibodies 
to Jo-1  are found  in  25-30%  of myositis patients (5-7),  particularly in  patients 
with  myositis and  interstitial  lung disease, where the  frequency is ~70%  (6,  7). 
In  this  paper  we  identify  a  second,  less  common  autoantibody  found  chiefly, 
though  not  exclusively,  in  myositis.  We  show  that  it  is  directed  at  another 
charging enzyme, threonyl-tRNA  synthetase,  and  that  the  antigenic  site recog- 
nized by the human autoantibody differs from that recognized by an experimen- 
tal antibody raised  in  rabbits.  We discuss  the  association  between  myositis and 
autoantibodies to tRNA-related antigens. 
Patients and  Methods 
Patients.  Five  examples  of the  PL-7  precipitin  system  were  studied:  Three  were 
obtained in a survey of 84 patients with myositis, the fourth from a study of 10 myositis 
sera  giving cytoplasmic immunofluorescence on  the  HEp-2  cell  line,  and  the  fifth  by 
screening sera from >1,000  patients with  other forms of systemic autoimmune disease 
(8), using counterimmunoelectrophoresis (CIE) (9). 
tmmunofluorescence.  Indirect immunofluorescence was performed with HEp-2 cells as 
substrate using fluorescein-labeled anti-human immunoglobulin provided by the supplier 
(Immunoconcepts, Inc., Sacramento, CA). Serum was diluted  1:40 in phosphate-buffered 
saline (PBS). Slides were read on a Nikon Optiphot ultraviolet microscope equipped with 
filters for fluorescein. 
Preparation oflgG.  All experiments used lgG isolated from serum by chromatography 
on DEAE-Sephadex A-50 columns run in 0.01  M Na phosphate at pH 7.2. Fractions with 
absorbance >0.8 at 280 nm were pooled, restored to  150  mM NaCI by the addition of 
salt, and held at -20°C. As used, IgG stocks were generally 0.7-1  mg/ml. 
Cell Labeling.  For [35S]methionine labeling, subconfluent HeLa cell monolayers were 
incubated for 5 h with [3'~S]methionine  (New England Nuclear, Boston, MA) at 0.5 mCi/ 
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ml in methionine-free medium (3 ml per 10-cm plate). The cells were washed once with 
ice-cold PBS, harvested, and lysed in 2 vol (~0.1  ml/plate) of buffer A (10 mM Tris-HCl, 
pH 7.5, 0.14 M NaC1,  1.5  mM MgCI2, 0.5% Nonidet P-40). The extract was frozen and 
thawed three times and stored at -70°C. 
For ,S2p labeling, HeLa cells in suspension culture were washed twice in phosphate-free 
medium, resuspended at 5 ×  105 cells/ml in phosphate-free medium containing 1% serum, 
and incubated for  17 h  with  [32P]phosphate (New England  Nuclear) at 30 mCi/100  ml 
culture. Cells were then harvested, washed, resuspended in buffer A (2 ml/100 ml culture), 
frozen and thawed three times, and stored at -20°C. 
Immunoprecipitation.  Unless otherwise specified, all procedures were carried out at 0- 
4°C  in  Eppendorf Microfuge  tubes as previously described  (10),  using  the  Brinkman 
Microfuge (Brinkman  Instruments,  Inc.,  Westbury,  NY).  Immune complexes were re- 
covered by adsorption  to protein  A  in  the  form of a  10%  suspension of Staphylococcus 
aureus (IgGSORB; Tufts Medical Center, Boston, MA) in buffer C (50 mM Tris-HCI, pH 
7.4,  150 mM NaCI, 5 mM EDTA, 0.5% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% 
sodium dodecyl sulfate  [SDS])  containing  bovine serum albumin  (BSA),  2  mg/ml.  For 
larger preparative immunoprecipitations, protein  A-Sepharose CL-4B (Pharmacia Fine 
Chemicals, P~scataway,  N  J) was easier to handle. 
The cell extract was centrifuged for 5  min,  precleared with  1/10 vol of IgGSORB in 
buffer C with BSA for 5 rain, and diluted  1:1  in  buffer C with BSA. Aliquots of 25 #l 
were incubated with 10 ~tl of lgG for 20 min, then with 50 ttl IgGSORB for 10 min, with 
regular mixing in both cases. After centrifugation for 20 s, the pellet was washed six times 
in 0.8  ml buffer C. Proteins were detached from the pellet by boiling in 2× gel sample 
buffer and resolved by electrophoresis on 15% SDS-polyacrylamide gels (11) and fluorog- 
raphy (12).  For analysis of RNA the pellet was boiled in 400 ttl of a buffer containing I 0 
mM Tris-HCl, pH 7.4, 250 mM NaCI, 0.5% SDS, and 25 ttg/ml calf liver tRNA, followed 
by phenol and chloroform extractions and precipitation with ethanol. RNAs were resolved 
using 7 M urea/10% polyacrylamide gels and were visualized by autoradiography, in some 
cases with the assistance of intensifier screens. 
Analysis of RNA and Protein.  Immunoprecipitated RNA was eluted from the gel by 
crushing and soaking in  10  mM Tris-HCl, pH 7.4,  1 mM EDTA, 0.5%  SDS, extracted 
with phenol and chloroform, and recovered by ethanol precipitation.  Fingerprints were 
prepared  by digestion  with  ribonuclease  TI,  followed  by electrophoresis on  cellulose 
acetate paper in the first dimension, and homochromatography on DEAE-cellulose thin 
layers using homomix C in the second dimension (13).  Minor nucleotides were separated 
by two-dimensional chromatography (14) after digestion with a mixture of ribonucleases 
A, Tl, and T2 (13).  Radioactivity was detected by autoradiography. 
For partial proteolysis, immunoprecipitated protein was eluted from the dried gel after 
fluorography by boiling in a  solution containing 0.5%  SDS,  10 mM 2-mercaptoethanol, 
10 mM Tris-HCl, pH 7.4. Aliquots of the proteins to be compared, containing approxi- 
mately equal  radioactivity, were incubated  with  varying quantities of protease from S. 
aureus strain V8 (15). After digestion for 15 min at 37 °C, the products were resolved by 
electrophoresis in SDS-20% polyacrylamide gels (11). 
Antigen Depletion.  Protein A-Sepharose, equilibrated and suspended at 15% vol/vol in 
buffer D (10 mM Tris-HCI, pH 7.4, 140 mM NaCI, 1.5 mM MgCI2, 0.5 mM dithiothreitol 
[DTT]), was incubated with  0.75  ml IgG for 20 min. After six  washes in buffer D the 
protein A-Sepharose was incubated with  100 #1 of HeLa cell extract for 30  min. Both 
incubations were at 4 °C with constant mixing. The final supernatant was held at -70 ° C. 
In  aminoacylation  assays  the  volume  of extract  used  was  adjusted  according  to  its 
absorbance at 280 nm to allow for dilution (1.6-2-fold) during the depletion procedure. 
Aminoacylation  of tRNA.  An extract containing aminoacyl-tRNA synthetases was pre- 
pared using a modification of the method described previously (16).  HeLa cells grown in 
suspension  culture  were harvested,  washed twice in  cold PBS,  suspended  in  2.5  vol of 
buffer E (10  mM Tris-HC1, pH 7.4,  1.5  mM  MgCI~,  15  mM  KCI, 0.5  mM  DTT), and 
allowed to swell for 10 min on ice. After disruption using a Dounce homogenizer, NaCI 
was added to 0.14  M, and the lysate was centrifuged at 10,000 g for 10 min and then at 422  ANT1-THREONYL-tRNA  SYNTHETASE  AND  MYOSITIS 
100,000 g for 2 h. The resultant supernatant, avoiding the fatty layer, was dialyzed for 
16 h against two changes of buffer E. 
Aminoacylation reactions contained the following, in a volume of 25 #l: 2.5-5 ttl of the 
HeLa cell extract; 90 ttg calf liver tRNA (Boehringer Mannheim Biochemicals, Indian- 
apolis, IN); 3 #Ci radioactive amino acid plus 16 #M of the same amino acid in unlabeled 
form; 5 mM adenosine triphosphate, 0.5 mM guanosine triphosphate, and 0.5 mM cytidine 
triphosphate;  l0 mM  Tris-HC1, pH  7.4;  10 mM  MgCl~, 0.1  mM  EDTA, and 0.5  mM 
DTT; and varying amounts of IgG. The final concentration of monovalent cation (KCI 
and  NaC1) was  adjusted  to  60  mM.  Incubation  was  at  37°C,  and  5-ttl samples  were 
removed at various times, usually 0, 3, and  10 min, for determination of the amount of 
amino acid bound to tRNA by trichloroacetic acid precipitation and liquid scintillation 
counting (4). 
Results 
Antibody Frequency and Clinical Association.  A  precipitating antibody known 
as  PL-7  was  identified  in  three sera  from a  series of 84  patients  with  myositis 
studied at Hammersmith  Hospital, and a  fourth example was found among  10 
American myositis sera selected because they gave cytoplasmic immunofluores- 
cence. A fifth isolate came from a patient with a connective tissue disease without 
apparent myositis (Table I). All five isolates gave similar patterns of cytoplasmic 
immunofluorescence on HEp-2 cells (Fig.  1). By CIE with rabbit thymus extract, 
all five sera gave an identical precipitin line distinct from the lines given by other 
autoantibody  systems,  and  no  further  examples  were  detected  in  a  survey of 
> 1,000 patients with various forms of systemic autoimmune disease (8). 
Immunoprecipitation of the Antigen.  HeLa cell extracts labeled with [35S]methi- 
onine or with [S2p]phosphate were used in protein A-mediated immunoprecipi- 
tation  reactions.  All  five PL-7  isolates recognized a  protein of 80,000  daltons 
(Fig.  2A,  lanes  2-4).  This  protein  was  not  recognized  by  IgG  from  healthy 
controls  (lane  5)  or  patients  with  other  autoantibodies  (lane  6).  The  80,000 
dalton  protein was also phosphate labeled (8). Three to four bands  of RNA in 
the transfer RNA size range were coprecipitated in all cases (Fig.  3A, lanes 2- 
4).  In some experiments, up to four additional weaker bands of slightly greater 
mobility were also  seen  (Fig.  3B).  The  PL-7  RNAs  represent  a  subset  of the 
tRNA-sized  molecules  present  in  the  HeLa cell  extract  (Fig.  3A,  lane  6)  and 
were electrophoretically distinct from tRNA His precipitated by anti-Jo-1 antibod- 
ies (Fig.  3A, lane 5). In further experiments, the PL-7 RNAs were immunopre- 
cipitated from cytoplasmic but not nuclear extracts (data not shown). 
Nature of the Antigen.  These findings are consistent with the antigen being a 
TABLE  I 
Clinical Features in Five Patients with PL-7 Antibody 
1.  Female, age 49, developed an acute hepatitis followed by a 6 mo episode of myositis and persistent 
arthritis, tendinitis, and Raynaud's phenomenon. 
2.  Female, in her 40s, with dermatomyositis. 
3.  Male, age 57, developed polymyositis  on top of longstanding rheumatoid arthritis. 
4.  Female, age 55, with 5 yr history of dermatomyositis and interstitial lung disease. 
5.  Female,  age 39, developed arthritis and, subsequently, Raynaud's phenomenon, reflux esopha- 
gitis with stricture, pleurisy, pericarditis, maculopapular rash, and hyperpigmentation. DNA 
binding was normal; muscle weakness was not a feature. MATHEWS  ET  AL.  423 
FIGURE  1.  Localization  of PL-7  antigen.  Indirect  immunofluorescence on  a  substrate  of 
HEp-2 cells using PL-7 antibody, x  200. 
ribonucleoprotein complex.  To  discover whether the  antigenic component is 
RNA or protein in nature we carried out two types of experiments. First,  35S- 
labeled extracts were digested with ribonuclease before immunoprecipitation. 
As shown in Fig. 2B, the 80,000 dalton protein remained precipitable after this 
treatment (lane 3).  Second, 32P-labeled RNA isolated by phenol extraction was 
not precipitable by PL-7 antibody (Fig. 3B, lane 2) unless an extract of unlabeled 
HeLa cells was added (Fig. 3B, lane 3).  These experiments suggest that the PL- 
7 antigen is a protein capable of associating with one or more RNA molecules. 
Characterization  of the RNA.  The immunoprecipitated RNA was eluted from 
the gel and subjected to digestion with ribonuclease T1  for "fingerprinting", or 
with a  combination of ribonucleases A,  T1,  and  T2  for analysis of nucleotide 
composition. The fingerprint, shown in Fig. 4A, differed from that given by Jo- 
1 RNA (4) and appeared to contain two sets of spots. The major set was roughly 
of the complexity expected for an RNA of 70-80 nucleotides length, the size of 
tRNA. At least one oligonucleotide streaked in the second dimension, suggesting 
that it contained an unstable nucleotide. The presence of modified nucleotides 
characteristic of tRNA is shown in  Fig. 4B,  where minor spots can be seen in 
addition to the major spots for Ap, Up, Cp, and Gp. Several of the same minor 
nucleotides were also observed in the digest ofJo-1 tRNA (Fig. 4C), though in 
different  proportions.  As  expected,  minor  nucleotides  were  undetectable  in 
digests of ribosomal 5S RNA (Fig.  4D).  From these data we conclude that the 
predominant RNA in the PL-7  immunoprecipitate is a  single species of tRNA 
probably containing variable numbers of minor bases that  give rise to several 
bands upon gel electrophoresis. The results presented below indicate that this 
RNA  is  tRNA  TM.  It  is  not  clear  whether the  minor  spots  in  the  fingerprint 
pattern come from a second, isoaccepting tRNA  TM species or from an unrelated 
RNA. 
tRNA  Charging.  We  previously  (4)  identified  the Jo-1  antigen  as  histidyl- 
tRNA  synthetase by demonstrating that  the antibody inhibits  the charging of 
tRNA with histidine.  Following this analogy, we investigated the specificity of 
PL-7 antibody in  the same way, testing each amino acid in  turn since, in this 
case, we did not know the identity of the tRNA. Initial experiments revealed no 424  ANTI-THREONYL-tRNA  SYNTHETASE  AND  MYOSIT1S 
FIGURE 2.  lmmunoprecipitation  of PL-7  protein.  (A) Proteins were precipitated from sss- 
labeled  HeLa  cell  extracts  with  the  following antibodies:  (1)  rabbit  anti-threonyl-tRNA 
synthetase; (2-4) three isolates of PL-7; (5) normal human  IgG; (6) antibodies to PCNA and 
SL antigens (8,  17). (B) Proteins were immunoprecipitated by PL-7 antibody from HeLa cell 
extracts  that  were (1)  preincubated  for 5  rain  at  37°C with 0.5  mg/m[  ribonuclease A; (2) 
preincubated without ribonuclease; (3) not preincubated. 
consistent effect with any amino acid, but, when the sensitivity of the assay was 
raised by decreasing the amount of charging extract and increasing the amount 
of antibody in the reaction, a profound inhibition (~95%) of threonine charging 
became apparent (Fig. 5).  Control antibodies such as anti-Jo-1  (Fig. 5), anti-La, 
or  normal  IgG  (not  shown)  did  not  block aminoacylation with  threonine, al- 
though, as  expected, anti-Jo-1  did inhibit histidinylation of tRNA.  At the en- 
hanced level of sensitivity used in these experiments, fluctuations of up to +50% 
were seen in the charging of several other amino acids (Fig. 5), but none of them 
was inhibited as markedly as threonine. We assume these smaller inhibitions are 
due to nonspecific effects or possibly to the presence of lesser amounts of other 
antibodies. 
As shown in Fig. 6A the addition of increasing amounts of PL-7 IgG led to a 
progressive decrease in the rate of tRNA aminoacylation with threonine. All five 
isolates of PL-7  IgG displayed the inhibitory effect on threonine charging. To 
exclude the possibility that the block was due to the addition of a  nonspecific 
inhibitor, we carried out the depletion experiments shown in Fig. 6, B and C. 
When  the  charging  extract  was  treated  with  immobilized  PL-7  antibody  to 
rentove the corresponding antigen, subsequent aminoacylation with threonine 
was greatly reduced (Fig. 6B), but there was no appreciable effect on charging 
with histidine (Fig. 6 C). The converse was seen when the charging extract was 
depleted of Jo-I  antigen. In this type of experiment the fluctuations seen with 
other amino acids  were  much  less  evident.  Further experiments (not  shown) MATHEWS  ET  AL.  425 
FIGURE 3.  Immunoprecipitation of PL-7 RNA. (A) lmmunoprecipitations from s~P-labeled 
HeLa cell extracts were carried out with (1) normal IgG; (2-4)  three PL-7 isolates; (5) anti-Jo- 
1 lgG. Lane 6 contains total cellular RNA as marker. (B) Immunoprecipitations were carried 
out with PL-7 lgG from (1) untreated 3~P-labeled HeLa cell extract; (2) s~P-RNA extracted 
with phenol and chloroform; (3) ~2P-RNA plus an equivalent amount of unlabeled HeLa cell 
extract. 
ruled  out  the  possibility  that  PL-7  antibody  discharges  preformed  threonyl- 
tRNA,  so we concluded  that  most probably the  PL-7 antigen  is threonyl-tRNA 
synthetase. 
Antibody to Threonyl-tRNA Synthetase.  To confirm this identification we carried 426  ANT1-THREONYL-tRNA  SYNTHETASE AND  MYOSITIS 
FIGURE 4.  Analysis  of immunoprecipitated RNA. (.4) Fingerprint of PL-7 RNA digested 
with ribonuclease Tl. (B-D) Nucleotide  composition of PL-7 RNA,  Jo-I RNA, and ribosomal 
5S RNA, respectively. 
out immunoprecipitations with an antibody (18) raised in rabbits against purified 
rat  threonyl-tRNA  synthetase  (19),  generously  provided  by  Dr.  S.  Arfin.  As 
expected, extracts depleted by pretreatment  with this antibody showed greatly 
reduced aminoacylation  with  threonine,  but no diminution  in  the charging  of 
other amino acids (not shown). The rabbit antibody immunoprecipitated  a  35S- 
labeled protein with the same electrophoretic mobility as PL-7 (Fig. 2A, lane 1), 
and  extracts  precleared  with  the  human  autoantibody  contained  no  protein 
reactive with either the human or rabbit antibody on subsequent immunoprecip- MATHEWS ET AL.  427 
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AIo  Asn  Cys  Glu  His  Leu  Met  Pro  Thr  Tyr 
Arg  Asp  Gin  Gly  lie  Lys  Phe  Ser  Try  Vol 
FIGURE 5.  Screening for an inhibitory effect of PL-7 antibody on aminoacylation of tRNA. 
Four  charging reactions were set  up  with  each  labeled amino acid:  two control reactions 
contained no IgG or 10 #l of normal IgG, and two experimental reactions contained 10 #l of 
anti-Jo-1 or PL-7 lgG. The extent of aminoacylation in the presence of each autoantibody is 
expressed as a percentage of the average of the two control reactions. 
itation (Fig. 7 A, lanes 3 and 4). Preclearing with the rabbit antibody reduced the 
precipitation of the 80,000  dalton protein by either antibody (Fig.  7A, lanes 5 
and 6), but did not eliminate it, presumably because of the lower activity of the 
experimental antibody (see Fig. 2A). These precleared extracts contained undi- 
minished amounts of other cellular antigens such as PCNA (12,  13) (not shown). 
In a more direct test of identity, the peptide composition of the immunoprecip- 
itated proteins were compared. Partial proteolysis using Staphylococcus aureus V8 
protease (15) gave similar polypeptide patterns with material immunoprecipitated 
by either rabbit antibody (Fig.  7B,  lanes 5-8) or human antibodies (lanes 1-4 
and  9-12).  These  results  confirm  that  the  PL-7  antigen  is  threonyl-tRNA 
synthetase. 
Different Antigenic Sites.  Surprisingly, in contrast to  PL-7 autoantibody, the 
rabbit  antibody failed to  immunoprecipitate tRNA  from a  ~2p-labeled extract 
although the amount of protein precipitated by the two antibodies was compa- 
rable (Fig. 8A). The experiments shown in Fig. 8B were carried out to exclude 
the possibility that the rabbit  IgG preparation contained ribonucIease or some 4
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FIGURE 7.  Identity of PL-7 antigen with threonyl-tRNA synthetase. (A) Immunoprecipita- 
tions  were  carried  out  with  PL-7  antibody (lanes  1,  3,  and  5)  and  anti-threonyl-tRNA 
synthetase (lanes 2, 4, and 6) from precleared [35S]methionine-labeled  HeLa cell extracts. The 
extracts were precleared with control IgG (lanes 1 and 2), PL-7 IgG (lanes 3 and 4), or rabbit 
anti-threonyl-tRNA synthetase (lanes 5 and 6). (B) Peptides were released by partial proteolysis 
from the 80,000 dalton protein immunoprecipitated by rabbit anti-threonyl-tRNA  synthetase 
(lanes 5-8) and two isolates of PL-7 antibody (lanes I-4 and 9-12). Each set shows, from left 
to right, digests with 0,  1, 10, and 100 ng of V8 protease. 
other interfering agent. The addition of human placental ribonuclease inhibitor 
to the rabbit  IgG preparation did not lead to the appearance of tRNA in  the 
immunoprecipitate (Fig. 8B, lane 2), nor did the rabbit antibody prevent immu- 
noprecipitation  of tRNA  by  PL-7  antibody  (lane  3).  The  slight  reduction  in 
tRNA  TM  precipitated in the presence of the rabbit antibody (compare Fig.  8B, 
lanes 3  and  5)  was  also  seen with  tRNA  his  precipitated by anti-Jo-1  antibody 
(lanes 4 and 6) and is therefore presumably due to overloading of the protein A 
adsorbent.  Since the human autoantibody precipitates tRNA with the enzyme 
whereas the rabbit antibody does not, we conclude that the two antibodies bind 
to different sites on the antigen. 
Discussion 
We have shown that the PL-7 antibody is directed at threonyl-tRNA synthetase. 
It precipitates a set of tRNAs bound to an 80,000 dalton protein and it specifically 
blocks the charging of tRNA with threonine. The protein moiety of the ribo- 
nucleoprotein complex is the antigenic component, and its molecular weight is 
in  close agreement with  measurements on the pure enzyme by Dignam et al. 430  ANTI-THREONYL-tRNA  SYNTHETASE  AND  MYOSITIS 
FIGURE 8.  Contrasting reactivities of rabbit and human antibodies to threonyl-tRNA synthe- 
tase. (A) Immunoprecipitations  using 35S- and s2P-labeled extracts were carried out with the 
amounts of rabbit anti-threonyl-tRNA synthetase and PL-7 IgG specified. (B) Immunoprecip- 
itations  from  s2P-labeled  extracts  were carried  out  with  10  /~g rabbit  anti-threonyl-tRNA 
synthetase (lanes 1-4) in the presence of the following supplements: (1) none; (2) ribonuclease 
inhibitor, 60 U (Rnasin; Promega-Biotec, Madison, WI); (3)  1 ~g PL-7 IgG; (4)  1 ug anti-Jo-1 
IgG.  (5  and  6)  1 /~g PL-7  lgG (5)  and  1 /~g anti-Jo-I  IgG (6)  in  the absence  of the  rabbit 
antibody. 
(19). These workers obtained an estimate of 80,000 daitons with the gel system 
used  by  us  and  85,000  daltons  with  another  gel  system;  the  native  enzyme 
behaved as a dimer of apparently identical subunits with an aggregate molecular 
mass of 154,000 daltons. Antibodies raised in rabbits against the purified enzyme 
recognize a  protein  that  is identical  with the  PL-7 antigen  in  size and  peptide 
composition, and by the immunological criterion of the preabsorption test. 
Although a  rather  uncommon  specificity, four of the five PL-7 isolates were 
from cases of myositis. Likewise, the more frequent anti-Jo-1  antibody, directed 
at histidyl-tRNA synthetase, is closely associated with myositis, where it marks a 
subset of patients with fibrosing aiveolitis and other overlap features (6, 7). From 
our own work (20), at least three additional RNAs oftRNA size are immunopre- 
cipitated  by autoantibodies.  Two of these,  Mas  and  Fer,  were  found  only  in 
myositis (Table  II).  A  third  antibody system, initially  named  tRNA-1  (21) and 
also represented by serum Ha (22), appears to involve alanyl-tRNA synthetase. ~ 
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This antibody has been found in one case of systemic sclerosis (SS) with myositis, 
two cases of SLE (one with myositis), one case of juvenile rheumatoid arthritis, 
and in a healthy control; thus, only two of the patients had myositis (22). ~ Two 
other tRNAs immunoprecipitated by myositis sera have been reported (21, 22) 
and are listed below  the line  in  Table  II,  since they may overlap with  those 
discussed above. Thus, of the five or more independent antibody systems involv- 
ing RNA of tRNA size, all have been found in myositis, and all but one have 
been found chiefly or only in this condition. 
Considering the large number of sera from other connective tissue diseases 
that  have  been  studied  by  immunoprecipitation  (8,  21,  23),  a  link  between 
myositis and  tRNA-related antigens  is  now clearly established.  However,  the 
correlation between myositis and tRNA is far from absolute. First, the tRNA-1 
antibody was found equally often in other diseases. Second, the Mas RNA may 
not be a  tRNA although  it  is similar in  size.  Third,  while most  myositis sera 
contain autoantibodies of some sort (3,  24),  no more than a  third  have been 
shown to recognize tRNA-related antigens. In particular, the Pm-Scl, Mi-1, and 
RNP antibodies do not recognize tRNA. The Pm-Scl antigen appears to be part 
of a complex containing three polypeptides of molecular masses 26,000,  31,000, 
and 36,000 daltons (8),  the Mi-1 antigen has not been detected by immunopre- 
cipitation (unpublished results), and the RNP antigen contains several polypep- 
tides complexed with U 1-RNA (8, 25). 
Nevertheless, the autoimmune response to aminoacyi-tRNA synthetases still 
appears to be closely associated with myositis. We have suggested a mechanism 
whereby the infection of genetically predisposed individuals by a particular virus 
such as coxsackie might lead to both myositis and the generation of antibody to 
histidyi-tRNA synthetase (4).  This  hypothesis proposes  that  viral  nucleic acid 
imitating tRNA His interacts with the enzyme and renders it immunogenic. An- 
TABLE  II 
Summary of tRNA- and Myositis-related Autoantibodies 
Number  Anti-  of exam-  Disease association 
body  pies  (frequency) 
system  known 
Antigen  References 
jo-1  >50  Myositis (25-30%), myositis  Histidyl-tRNA  4-7 
with interstitial lung disease  synthetase 
(70%) 
PL-7  5  Myositis (3-4%). other con-  Threonyl-tRNA  This paper 
nective tissue diseases  synthetase 
(-0.1%) 
Mas  2  Myositis (-2%)  ?tRNA  8 
Fer  1  Myositis (~ 1%)  Protein (?EF-Tu)  Footnote 2 
tRNA-1  5  SS with myositis, SLE with  Alanyl-tRNA  21, 22, and foot- 
myositis, SLE, juvenile  synthetase, ?tRNA  A~  note 2 
rheumatoid arthritis, 
healthy control 
tRNA-2  2  Myositis, SLE  Protein  21 
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other  virus  or another  strain  of coxsackievirus  might  induce the antibody to 
threonyl-tRNA  synthetase  in  like  fashion.  Although  direct  support  for  this 
specific hypothesis is still lacking, the data do fit well with the more general idea 
that autoantibodies result from the interaction of foreign or altered nucleic acid 
with host cell proteins.  Interestingly, as we have discussed elsewhere (26),  the 
data fit less well with the antiidiotype hypothesis, at least in the form advanced 
by Piotz (27), although they do not exclude it. 
The  rabbit  and  human  antibodies  have  different specificities.  Rabbit  anti- 
threonyl-tRNA synthetase fails to precipitate tRNA with the enzyme, presumably 
because it binds in such a way as to obstruct the attachment of tRNA or binds to 
a form of the enzyme incapable of complexing with tRNA. It may be significant 
that the immunogen in this case was purified protein.  On  the other hand, the 
human autoantibody can recognize the enzyme in an RNA-bound state, and it is 
tempting to deduce, in support of our hypothesis (4), that the human autoimmune 
response is elicited by RNA-bound antigen. 
Summary 
An autoantibody known as PL-7 was found in the serum of four patients with 
myositis and one with a systemic lupus erythematosus-like syndrome. The PL-7 
antigen is an 80,000  dalton polypeptide that coprecipitates with transfer RNA. 
In  aminoacylation reactions,  PL-7  IgG  inhibited  the  charging  of tRNA  with 
tbreonine  but  had  little  or  no  effect  on  charging  with  other  amino  acids. 
Experimental antibodies raised against purified threonyl-tRNA synthetase rec- 
ognized the same 80,000  dalton polypeptide, but tRNA was not coprecipitated. 
We conclude that  PL-7 antibody is directed at threonyl-tRNA synthetase, and 
that  different antigenic  sites  are  recognized  by  the  human  and  experimental 
autoantibodies.  Our  findings emphasize the link between myositis and autoim- 
munity to tRNA-related structures. 
We thank Miss C.  Herrmann and Mr. C.  Bunn for expert technical assistance.  We are 
most grateful to Dr. S. Arfin for the generous gift of rabbit antiserum to purified threonyl- 
tRNA synthetase, to Dr.  M. Deutscher for helpful suggestions, and to Dr.  E. Hamilton 
and Dr. M. Turner-Warwick for clinical details on two patients. 
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